Overview

Nivolumab, Ipilimumab and OTSGC-A24 Therapeutic Peptide Vaccine in Gastric Cancer - a Combination Immunotherapy Phase Ib Study.

Status:
Recruiting

Trial end date:
2024-03-01

Target enrollment:

Participant gender:

Summary

The primary hypothesis is that cancer vaccine can convert non-immunogenic gastric cancer into immunogenic phenotype susceptible to PD1 inhibition. This would lead to an improved radiological response rate and favorable immune contexture for immune checkpoint blockade

Phase:

Phase 1

Details

Lead Sponsor:

National University Hospital, Singapore

Collaborators:

Bristol-Myers Squibb
OncoTherapy Science, Inc.

Treatments:

Antibodies, Monoclonal
Ipilimumab
Nivolumab